

## S 3384

### Lowering Prescription Drug Prices for America's Seniors and Families Act of 2020

**Congress:** 116 (2019–2021, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Mar 3, 2020

**Current Status:** Read twice and referred to the Committee on Finance.

**Latest Action:** Read twice and referred to the Committee on Finance. (Mar 3, 2020)

**Official Text:** <https://www.congress.gov/bill/116th-congress/senate-bill/3384>

#### Sponsor

**Name:** Sen. McSally, Martha [R-AZ]

**Party:** Republican • **State:** AZ • **Chamber:** Senate

#### Cosponsors

No cosponsors are listed for this bill.

#### Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Mar 3, 2020

#### Subjects & Policy Tags

##### Policy Area:

Health

#### Related Bills

Bill	Relationship	Last Action
116 HR 2374	Related bill	Dec 24, 2020: Placed on the Union Calendar, Calendar No. 577.
116 S 1224	Related bill	Jun 28, 2019: Placed on Senate Legislative Calendar under General Orders. Calendar No. 130.
116 HR 2455	Related bill	May 2, 2019: Referred to the Subcommittee on Health.
116 S 1169	Related bill	Apr 11, 2019: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
116 HR 478	Related bill	Jan 25, 2019: Referred to the Subcommittee on Health.
116 S 61	Related bill	Jan 9, 2019: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
116 S 64	Related bill	Jan 9, 2019: Read twice and referred to the Committee on the Judiciary.

## **Lowering Prescription Drug Prices for America's Seniors and Families Act of 2020**

This bill makes a series of changes to requirements relating to prescription drug prices. Among other changes, the bill requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain covered drugs under the Medicare prescription drug benefit, allows individuals to import certain drugs from Canada to fill personal prescriptions, and establishes specific enforcement actions against patent infringement agreements that involve generic drug manufacturers and have anticompetitive effects.

### **Actions Timeline**

---

- **Mar 3, 2020:** Introduced in Senate
- **Mar 3, 2020:** Read twice and referred to the Committee on Finance.